STUDY DESIGN

Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for patients with metastatic triple-negative breast cancer (mTNBC) who have previously received ≥2 prior systemic therapies.¹ Its remarkable efficacy had been compared to conventional chemotherapy (CTx) and demonstrated superiority over single-agent CTx in the ASCENT study, where it significantly reduced the risk of disease progression or death by 60% and offered a 50% overall survival benefit when compared to CTx.¹ To evaluate the clinical efficacy of SG in real-world settings, a retrospective, observational cohort study was commenced to investigate the real-world application of SG as a second-line (2L) or later (3L+) treatment for patients with mTNBC.¹

A total of 230 patients who were diagnosed with mTNBC and prescribed SG as a 2L or 3L+ treatment were included in this real-world analysis and followed up from April 2020 to May 2022, cumulating a median follow-up of 7.2 months.¹ Among the patient population, 33% of patients received SG as a 2L treatment.¹ The treatment regimen of SG in this population consisted of a median of 9 doses with a starting dose of 10mg/kg that lasted for a median duration of 3.8 months.¹ At the end of the study, 9% of patients continued their SG treatment.¹

The key endpoints of this real-world analysis consisted of the real-world clinical outcomes of the study population, which included real-world overall survival (rwOS), real-world progression-free survival (rwPFS), time to next treatment or death (TTNTD), SG treatment discontinuation and modification rates, and incident adverse events (AEs).

“The effectiveness and tolerability profile of sacituzumab govitecan in this broad and racially diverse real-world population with poorer prognostic factors was consistent with findings from the phase 3 ASCENT study.”

^{Dr. Kevin Kalinsky
Winship Cancer Institute,
Emory University,
Atlanta, Georgia, USA}